377 the non-alcoholic fatty liver disease-promoting variant lyplal1-rs12137855-c increases risk of common metabolic diseases independently of its anthropometric effects in both men and women

had >50% higher risk of HCC (adj HR=1.54, 95% CI: 1.12 -2.11) while adjusting for glycemic control.In a subgroup of patients with good glycemic control (HbA1c <7% for >80% of follow up) compared with patients on metformin alone, those treated with both insulin and sulfonylureas had a 5-fold higher risk of HCC (adj HR=4.24, 95% CI: 1.01 -17.83).Conclusions: In NAFLD patients with diabetes, metformin was associated with a reduced risk of HCC compared to the use of insulin with and without sulfonylureas.This effect was independent of glycemic control.Glycemic control was not associated with the risk of incident HCC.